CD274 and neoplasm: The analysis of OS according to PD-L1 tumour expression status showed that ICIs significantly improved OS in patients with PD-L1-positive tumours (HR = 0.82 95% CI: 0.67–0.99; p = 0.04) in comparison to PD-L1-negative patients (HR = 1.04 95% CI: 0.77–1.42; p = 0.80) Figure 2.